相关临床试验
141
51 进行中
药物批准
12
批准总数
监管机构
3
监管机构数
成立时间
N/A
进行中（未招募）
48
34.0%
Available
1
0.7%
已完成
72
51.1%
Enrolling By Invitation
1
0.7%
尚未招募
2
1.4%
招募中
11
7.8%
终止
5
3.5%
撤回
1
0.7%
- The FDA has approved Orzeyful (oveporexton), the first drug designed to mimic orexin, the brain peptide missing in people with narcolepsy type 1. - In two phase 3 trials, oveporexton roughly doubled sleep latency versus placebo and cut weekly cataplexy rates by up to 88.8%. - Adverse events occurred in 86 to 89 percent of oveporexton-treated participants, most commonly increased urinary frequency and transient insomnia. - Alkermes and Eli Lilly are pursuing similar orexin-targeting programs, with Lilly agreeing to pay up to $7.8bn for Centessa Pharmaceuticals.
- Mentari Therapeutics has named Greg Divis, former Avadel CEO, as its new chief executive officer effective July 20, 2026. - Divis brings over 30 years of industry experience, including leading Avadel through FDA approval and commercial launch of Lumryz and its $2.4 billion acquisition by Alkermes. - Mentari is advancing two migraine prevention candidates: MT-001, an anti-PACAP monoclonal antibody with regulatory filings expected mid-year 2026, and MT-002, an anti-PACAP/anti-CGRP bispecific antibody with filings planned for Q1 2027. - The company's pipeline targets the PACAP pathway independently of CGRP, aiming to address unmet needs for patients who do not achieve adequate symptom control with current therapies.
- The SPDR S&P Pharmaceuticals ETF (XPH) delivered a 38.00% one-year total return as of June 3, 2026, outperforming the First Trust NYSE Arca Biotech ETF (FBT) at 35.90%. - XPH carries a lower expense ratio of 0.35% compared to FBT's 0.55%, offering a cost advantage for long-term investors in the pharmaceutical space. - Both ETFs concentrate 42% of assets in their top 10 holdings, with Corcept Therapeutics appearing as a top-10 position in each fund. - The SPDR Biotech ETF (XBI) posted a 58.30% one-year return but experienced a 54.70% maximum drawdown over five years, highlighting the higher volatility of the biotech sub-sector.
- More than three pharmaceutical companies are actively developing over four promising hypersomnia treatment candidates, signaling growing innovation in sleep disorder management. - Avadel Pharmaceuticals received FDA orphan drug designation in June 2025 for Lumryz, an extended-release sodium oxybate therapy for idiopathic hypersomnia. - Alkermes initiated a Phase II trial in April 2025 evaluating ALKS 2680, a selective orexin receptor modulator, in patients with idiopathic hypersomnia across global sites. - Axsome Therapeutics reported positive Phase III results in November 2024 for AXS-12 (reboxetine), demonstrating significant reductions in cataplexy episodes.
- Monopar Therapeutics appointed Susan Rodriguez as Chief Commercial and Strategy Officer to lead commercial strategy as the company prepares for a planned New Drug Application submission for ALXN1840 in the first half of 2026. - ALXN1840 represents the first major advancement in Wilson disease treatment in decades, with a novel mechanism of action as an albumin tripartite complex activator that differentiates it from current first-line therapies. - The company reported positive long-term efficacy and safety data from 255 patients with a median treatment duration of 2.63 years, demonstrating statistically significant improvement in copper balance. - Monopar strengthened its balance sheet with approximately $91.9 million raised through an underwritten public offering and expects current funds to support operations through at least December 31, 2027.
